Total Payments
$82,723
2021 Payments
$6,718
Companies
52
Transactions
539
Medicare Patients
1,022
Medicare Billing
$170,378
Payment Breakdown by Category
Other$50,920 (61.6%)
Consulting$12,818 (15.5%)
Food & Beverage$12,219 (14.8%)
Travel$6,294 (7.6%)
Education$471.81 (0.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $50,920 | 33 | 61.6% |
| Consulting Fee | $12,818 | 10 | 15.5% |
| Food and Beverage | $12,219 | 453 | 14.8% |
| Travel and Lodging | $6,294 | 28 | 7.6% |
| Education | $471.81 | 15 | 0.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Lilly USA, LLC | $47,499 | 122 | $0 (2021) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $19,255 | 29 | $0 (2019) |
| Millennium Pharmaceuticals, Inc. | $4,162 | 4 | $0 (2017) |
| E.R. Squibb & Sons, L.L.C. | $2,041 | 43 | $0 (2021) |
| GlaxoSmithKline, LLC. | $1,939 | 2 | $0 (2021) |
| Novartis Pharmaceuticals Corporation | $974.24 | 41 | $0 (2019) |
| Genentech USA, Inc. | $717.63 | 36 | $0 (2019) |
| Merck Sharp & Dohme Corporation | $531.53 | 19 | $0 (2018) |
| Janssen Biotech, Inc. | $507.16 | 27 | $0 (2019) |
| Incyte Corporation | $439.24 | 9 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2021 | $6,718 | 10 | Lilly USA, LLC ($4,725) |
| 2020 | $9,212 | 43 | Lilly USA, LLC ($8,899) |
| 2019 | $31,422 | 101 | Lilly USA, LLC ($25,720) |
| 2018 | $20,068 | 195 | Boehringer Ingelheim Pharmaceuticals, Inc. ($8,894) |
| 2017 | $15,302 | 190 | Boehringer Ingelheim Pharmaceuticals, Inc. ($6,538) |
All Payment Transactions
539 individual payment records from CMS Open Payments — Page 1 of 22
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/28/2021 | Lilly USA, LLC | VERZENIO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $900.00 | General |
| Category: Oncology | ||||||
| 09/01/2021 | Lilly USA, LLC | VERZENIO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $900.00 | General |
| Category: Oncology | ||||||
| 08/05/2021 | Lilly USA, LLC | VERZENIO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $450.00 | General |
| Category: Oncology | ||||||
| 06/23/2021 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $24.44 | General |
| Category: Oncology | ||||||
| 06/16/2021 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $20.77 | General |
| Category: ONC | ||||||
| 06/01/2021 | Gilead Sciences, Inc. | — | Education | In-kind items and services | $11.92 | General |
| 05/20/2021 | Lilly USA, LLC | VERZENIO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $900.00 | General |
| Category: Oncology | ||||||
| 05/06/2021 | GlaxoSmithKline, LLC. | BLENREP (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,920.00 | General |
| Category: ONCOLOGY | ||||||
| 05/06/2021 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $15.92 | General |
| Category: Oncology | ||||||
| 02/25/2021 | Lilly USA, LLC | VERZENIO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,575.00 | General |
| Category: Oncology | ||||||
| 09/10/2020 | Lilly USA, LLC | VERZENIO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,125.00 | General |
| Category: Oncology | ||||||
| 07/13/2020 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Education | Cash or cash equivalent | $9.38 | General |
| Category: Oncology | ||||||
| 03/09/2020 | Lilly USA, LLC | VERZENIO (Drug) | Travel and Lodging | Cash or cash equivalent | $44.00 | General |
| Category: Oncology | ||||||
| 03/09/2020 | Lilly USA, LLC | VERZENIO (Drug) | Travel and Lodging | Cash or cash equivalent | $23.00 | General |
| Category: Oncology | ||||||
| 03/09/2020 | Lilly USA, LLC | VERZENIO (Drug) | Food and Beverage | Cash or cash equivalent | $8.26 | General |
| Category: Oncology | ||||||
| 03/09/2020 | Lilly USA, LLC | VERZENIO (Drug) | Food and Beverage | Cash or cash equivalent | $5.96 | General |
| Category: Oncology | ||||||
| 03/06/2020 | GlaxoSmithKline, LLC. | ZEJULA (Drug) | Food and Beverage | In-kind items and services | $18.62 | General |
| Category: ONCOLOGY | ||||||
| 02/26/2020 | Lilly USA, LLC | VERZENIO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,050.00 | General |
| Category: Oncology | ||||||
| 02/26/2020 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $18.75 | General |
| 02/21/2020 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $547.87 | General |
| 02/20/2020 | Lilly USA, LLC | — | Food and Beverage | In-kind items and services | $133.73 | General |
| 02/20/2020 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $95.00 | General |
| 02/20/2020 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $77.78 | General |
| 02/20/2020 | Lilly USA, LLC | — | Food and Beverage | In-kind items and services | $43.88 | General |
| 02/20/2020 | Lilly USA, LLC | — | Food and Beverage | In-kind items and services | $41.47 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2021 | 6 | 425 | 731 | $226,565 | $83,537 |
| 2020 | 8 | 597 | 934 | $282,923 | $86,841 |
Total Patients
1,022
Total Services
1,665
Medicare Billing
$170,378
Procedure Codes
15
All Medicare Procedures & Services
15 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 247 | 493 | $145,435 | $52,636 | 36.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 83 | 129 | $51,600 | $19,435 | 37.7% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2021 | 42 | 56 | $9,485 | $5,182 | 54.6% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 15 | 15 | $8,175 | $2,756 | 33.7% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 17 | 17 | $7,565 | $2,361 | 31.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 21 | 21 | $4,305 | $1,168 | 27.1% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 273 | 536 | $158,120 | $47,316 | 29.9% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 151 | 210 | $84,000 | $22,989 | 27.4% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 58 | 67 | $10,050 | $6,433 | 64.0% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 21 | 21 | $11,445 | $3,741 | 32.7% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 18 | 18 | $8,010 | $2,606 | 32.5% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 13 | 19 | $5,605 | $1,308 | 23.3% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 18 | 18 | $1,890 | $1,193 | 63.1% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 13 | 13 | $2,665 | $862.68 | 32.4% |
| G2012 | Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m servic | Office | 2020 | 32 | 32 | $1,138 | $393.37 | 34.6% |
About Dr. Marvin Feldman, MD
Dr. Marvin Feldman, MD is a Hematology & Oncology healthcare provider based in Baltimore, Maryland. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/20/2006. The National Provider Identifier (NPI) number assigned to this provider is 1336254424.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Marvin Feldman, MD has received a total of $82,723 in payments from pharmaceutical and medical device companies, with $6,718 received in 2021. These payments were reported across 539 transactions from 52 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($50,920).
As a Medicare-enrolled provider, Feldman has provided services to 1,022 Medicare beneficiaries, totaling 1,665 services with total Medicare billing of $170,378. Data is available for 2 years (2020–2021), covering 15 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Baltimore, MD
- Active Since 08/20/2006
- Last Updated 07/08/2007
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1336254424
Products in Payments
- VERZENIO (Drug) $43,872
- GILOTRIF (Drug) $19,255
- ALUNBRIG (Drug) $4,149
- BLENREP (Biological) $1,920
- OPDIVO (Biological) $1,069
- EMPLICITI (Biological) $559.66
- KEYTRUDA (Biological) $469.20
- ADCETRIS (Biological) $377.10
- Cabometyx (Drug) $316.83
- JAKAFI (Drug) $295.22
- KISQALI (Drug) $289.06
- XTANDI (Drug) $285.29
- IMBRUVICA (Drug) $276.66
- JEVTANA (Drug) $255.35
- FOUNDATIONONE (Device) $252.13
- CYRAMZA (Drug) $177.57
- Nerlynx (Drug) $172.70
- TECENTRIQ (Biological) $171.24
- Kyprolis (Biological) $165.99
- VPRIV (Biological) $161.66
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Baltimore
Miss. Ani Balmanoukian, M.d, M.D
Hematology & Oncology — Payments: $842,199
Hematology & Oncology $842,199
Dr. Benjamin Levy, Md, MD
Hematology & Oncology — Payments: $814,882
Hematology & Oncology $814,882
Dr. Patrick Forde, M.d, M.D
Hematology & Oncology — Payments: $253,665
Hematology & Oncology $253,665
Josephine Feliciano, M.d, M.D
Hematology & Oncology — Payments: $125,936
Hematology & Oncology $125,936
Djordje Atanackovic, M.d, M.D
Hematology & Oncology — Payments: $117,434
Hematology & Oncology $117,434
Huzefa Bahrain, D.o, D.O
Hematology & Oncology — Payments: $103,816
Hematology & Oncology $103,816